SCHEMBL4798748

SCHEMBL4798748

Cc1cnc(Oc2ccc([NH])cc2Cl)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OXTR P30559 2/20 0.39
ACACB O00763 2/20 0.37
KMT2A Q03164 2/20 0.35
POLB P06746 2/20 0.35
LMNA P02545 2/20 0.35
MEN1 O00255 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HTT P42858 1/20 0.35
SLC6A2 P23975 4/20 0.35
SLC6A4 P31645 4/20 0.35
SLC6A3 Q01959 3/20 0.35
S1PR4 O95977 4/20 0.34
RXRA P19793 1/20 0.34
GRIN1 Q05586 1/20 0.34
GRIN2B Q13224 1/20 0.34
ACACA Q13085 1/20 0.34
GRM8 O00222 1/20 0.33
GRM7 Q14831 1/20 0.33
GRM4 Q14833 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4800373 0.84 OXTR (0.36) OXTRKMT2AMEN1SMN1; SMN2SLC6A2
SCHEMBL4797941 0.82 MAPT (0.41) OXTRKMT2AMEN1SMN1; SMN2ALDH1A1
SCHEMBL4798761 0.82 KDM4E (0.43) OXTRACACBKMT2APOLBLMNA
SCHEMBL4797986 0.79 LMNA (0.36) LMNASMN1; SMN2ALDH1A1HTTSLC6A2
SCHEMBL4799461 0.79 MPO (0.44) ACACBKMT2AMEN1SLC6A2SLC6A4
SCHEMBL4798364 0.78 HTT (0.34) KMT2AMEN1ALDH1A1HTTSLC6A2
SCHEMBL4798024 0.77 HTT (0.39) OXTRACACBKMT2ALMNAMEN1
SCHEMBL4795122 0.77 GRM4 (0.47) KMT2AMEN1SMN1; SMN2ALDH1A1HTT
SCHEMBL4799631 0.76 S1PR4 (0.37) ALDH1A1HTTS1PR4GRM4
SCHEMBL4797487 0.75 GRM4 (0.46) OXTRACACBLMNAALDH1A1S1PR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050159435-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth PFIZER INC 2005-07-21 US claimed
EP-1292591-B1 SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PROD INC (US) 2005-02-02 EP claimed
US-20020169165-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth PFIZER PRODUCTS INC. 2002-11-14 US claimed
US-7332493-B2 Substituted bicyclic derivatives for the treatment of abnormal cell growth OSI PHARMACEUTICALS (US) 2008-02-19 US disclosed
US-20050159435-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth PFIZER INC 2005-07-21 US disclosed
US-6890924-B2 Substituted bicyclic derivatives for the treatment of abnormal cell growth PFIZER INC (US) 2005-05-10 US disclosed
EP-1292591-B1 SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PROD INC (US) 2005-02-02 EP disclosed
US-20020169165-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth PFIZER PRODUCTS INC. 2002-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169165-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth CCNA1, CCNT1, CCNB1 OXTR 1355/4885ACACB 2259/4885KMT2A 3339/4885
US-20050159435-A1 Substituted bicyclic derivatives for the treatment of abnormal cell growth CCNA1, CCNT1, CCNB1 OXTR 1070/4885ACACB 2556/4885KMT2A 3112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.